Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states

Quest Diagnostics® (NYSE:DGX), a leading provider of diagnostic information services, today announce

UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the p

Quest Diagnostics (DGX) reported strong Q1 earnings, beating expectations and raising guidance. Anal

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the

Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and

Quest Diagnostics Q1 revenue grew 9.2% as organic volume surged. Discover how new partnerships and A

Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.45-$9.65 to $9.58-$9.78 vs $9.4

Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.50-$10.70 to $10.63-$10.83 vs $

Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $2.50 per share which beat the analyst c

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:DGX) with a In-Li

New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data t

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and

UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the p

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:DGX) with a In-Li

Barclays analyst Stephanie Davis maintains Quest Diagnostics (NYSE:DGX) with a Overweight and rai

Jefferies analyst Tycho Peterson maintains Quest Diagnostics (NYSE:DGX) with a Buy and raises the

Quest Diagnostics (NYSE: DGX) reported Q4 earnings of $2.42 per share, beating expectations. Sales w

Guidance for Full Year 2026The company estimates its full year 2026 guidance in the table below. The

Guidance for Full Year 2026The company estimates its full year 2026 guidance in the table below. The

Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $2.42 per share which beat the analyst c

The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Q

New test as sensitive as next-generation sequencing, and provides five-day specimen stability to sup

Collaboration enables patients to access the Octave MSDA test at Quest's approximately 7,000 pat

Gold prices suffered a sharp correction on Tuesday as investors locked in profits following this yea

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic c

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic c

It was a quiet Tuesday on Wall Street, as major indexes edged lower with investors pausing ahead of

Quest Diagnostics Q1 2025 revenue rose to $2.65 billion with EPS of $2.21, exceeding expectations; f

Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius M